COMPARATIVE EFFECTIVENESS OF TRIPLETS CONTAINING BORTEZOMIB (B), CARFILZOMIB (C), DARATUMUMAB (D), OR IXAZOMIB (I) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN ROUTINE CARE IN THE US

EHA Library, Ajai Chari, 267036

RESULTS FROM A POST-AUTHORIZATION SAFETY STUDY COMPARING LENALIDOMIDE-BASED WITH NON-LENALIDOMIDE-BASED TREATMENT IN TRANSPLANT-INELIGIBILE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

EHA Library, Valerio De Stefano, 267037

HONEUR (HEAMATOLOGY OUTCOMES NETWORK IN EUROPE) - DISTRIBUTED STATISTICS IN A FEDERATED MODEL TO SUPPORT REAL WORLD DATA RESEARCH IN HEMATOLOGY

EHA Library, Alun Passey, 267038

VENETOCLAX FOR THE TREATMENT OF MULTIPLE MYELOMA: OUTCOMES OUTSIDE OF CLINICAL TRIALS

EHA Library, M Hasib Sidiqi, 267039

NEXT-GENERATION SEQUENCING STUDY OF V(D)J REARRANGEMENTS ON NON-CR PATIENTS SHOWING MRD NEGATIVITY BY NEXT-GENERATION FLOW

EHA Library, Sung Min KIM, 267040

THE CRAB SCORE: A SIMPLE PROGNOSTIC TOOL IN MULTIPLE MYELOMA

EHA Library, Helena Bean, 267041

RESULTS OF THE DARATUMUMAB MONOTHERAPY EARLY ACCESS TREATMENT PROTOCOL (EAP) IN PATIENTS FROM EUROPE AND RUSSIA WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

EHA Library, Gordon Cook, 267042

IMMUNE CHECKPOINT (PD-1, PD-L1, PD-L2, AND CTLA-4) EXPRESSION IN PLASMA CELL MYELOMA

EHA Library, Min Young Lee, 267043

THE SIGNIFICANCE OF UNEXPECTED PHARMACOKINETICS OF DARATUMUMAB DURING LONG-TERM MONTHLY TREATMENT FOR MYELOMA

EHA Library, Linda Little, 267044

GCSF ALONE STEM CELL MOBILIZATION IN MULTIPLE MYELOMA PATIENTS CANDIDATES TO HIGH DOSE CHEMOTHERAPY: A MONOCENTRIC RETROSPECTIVE EXPERIENCE.

EHA Library, Stefania Bramanti, 267045

LIVING ALONE WITH MULTIPLE MYELOMA: THE NEXT-GENERATION CHALLENGE

EHA Library, Rafael Rios-Tamayo, 267046

INTEGRATION OF FOUR COLOUR FLOW TO PREDICT RELAPSE/PROGRESSION AND TIME TO NEXT TREATMENT IN MULTIPLE MYELOMA AFTER UPFRONT AUTOLOGOUS STEM CELL TRANSPLANT

EHA Library, Pedro Chorão, 267047

IDENTIFICATION OF THE TRUE HYPERDIPLOID MULTIPLE MYELOMA SUBSET BY COMBINING CONVENTIONAL KARYOTYPING AND FISH ANALYSIS

EHA Library, Gregorio Barilà, 267048

3-WEEKLY DARATUMUMAB-IMID-DEXAMETHASONE IS HIGHLY EFFICACIOUS, HENCE FINANCIALLY AFFORDABLE WITH ENORMOUS ECONOMIC IMPACT FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA IN LESS AFFLUENT COUNTRIES

EHA Library, Chor Sang Chim, 267049

RESULTS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS WITH RENAL FAILURE

EHA Library, Ayşe Tülin Tuğlular, 267050

IFN-Α TREATMENT NORMALIZES THE PLATELET COUNTS AND REDUCES QUIESCENT STEM CELLS IN A CALR-DEL52 TRANSGENIC MOUSE MODEL, IN VIVO.

EHA Library, Harini Nivarthi, 267053

SETD2 NON-GENOMIC LOSS OF FUNCTION IN ADVANCED SYSTEMIC MASTOCYTOSIS (SM): PATHOGENETIC AND THERAPEUTIC IMPLICATIONS

EHA Library, Manuela Mancini, 267054

DATA-DRIVEN ANALYSIS OF JAK2V617F KINETICS DURING INTERFERON-ALPHA2 TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA AND RELATED NEOPLASMS

EHA Library, Vibe Skov, 267055

ENHANCED SUPPORT OF MYELOFIBROSIS STEM CELLS IN NEXT GENERATION HUMANIZED MICE

EHA Library, Veronika Lysenko, 267056

A NOVEL ACTIVATING TPOR MUTATION IN ESSENTIAL THROMBOCYTHEMIA POINTS TO AN ACTIVATING EFFECT OF TRYPTOPHAN AND AROMATICS AT THE OUTSET OF THE TRANSMEMBRANE DOMAIN

EHA Library, Gabriel Levy, 267058

PROTEASOME INHIBITOR CARFILZOMIB HAS SYNTHETIC LETHALITY WITH RUXOLITINIB IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Simone Claudiani, 267059

BLOCKADE OF TNFR1 RATHER THAN TNFR2 IMPROVES HEMATOCRIT AND REDUCES BLOOD PRO-INFLAMMATORY CYTOKINE LEVELS IN THE VAV1-CRE X JAK2+/V617F MPN MOUSE MODEL

EHA Library, Peter Müller, 267060

THE ROLE OF THE THROMBOPOIETIN RECEPTOR (MPL) IN JAK2V617F-POSITIVE MYELOPLROLIFERATIVE NEOPLASMS

EHA Library, Kira Behrens, 267063

ANALYSIS OF UPR-RELATED GENE EXPRESSION IN CD34+ CELLS FROM PATIENTS WITH PRIMARY MYELOFIBROSIS REVEALS DOWNREGULATION OF UPR GENES AND REDUCTION OF APOPTOSIS

EHA Library, Paolo Catarsi, 267064

LIN-CD133+CD34+CD41+ HSPC REPRESENT A MEGAKARYOCYTE-PRIMED NEOPLASTIC FRACTION IN MPN PATIENTS WITH MYELOFIBROSIS

EHA Library, Vera Köhl, 267065

DISSECTING THE THERAPEUTIC MECHANISM OF RUXOLITINIB IN JAK2V617F MEDIATED MPNS REVEALED AN INHIBITION OF BOTH ONCOGENIC AND NON-ONCOGENIC CELLS BY DOWN REGULATION OF INFLAMMATORY CYTOKINE LEVELS

EHA Library, Sivahari Prasad Gorantla Gorantla, 267066

THE PHARMACOLOGICAL IGF1R-IRS1/2 INHIBITOR OSI-906 REDUCES ERYTHROID PROGENITORS AND INHIBITS STAT3 IN JAK2V617F KNOCKIN-MYELOPROLIFERATIVE NEOPLASM MICE

EHA Library, Jaqueline Fernandes, 267067

THE EFFECT OF HYDROXYUREA ON DNA METHYLATION AND GENE EXPRESSION IN POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA.

EHA Library, Stephania CONTRERAS, 267068

GLI-1, EFFECTOR OF CANONICAL HEDGEHOG SIGNALING PATHWAY, DOES NOT SEEM TO BE DYSREGULATED IN PATIENTS WITH MYELOFIBROSIS

EHA Library, Rajko Kusec, 267069

CURCUMIN INHIBITS PROLIFERATION AND INDUCES APOPTOSIS IN JAK2 MUTATED CELLS THROUGH THE INHIBITION OF JAK2/STAT AND MTORC1 PATHWAYS

EHA Library, Jessica Petiti, 267070

CAG PROMOTER DRIVEN C-MYC OVEREXPRESSION CAUSES RAPIDLY LETHAL CARDIOMYOPATHY

EHA Library, Sarolta Bojtiné Kovács, 267071

RESPONSE TO UP-FRONT AZACITIDINE IN JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML): INTERIM ANALYSIS OF THE PROSPECTIVE EUROPEAN MULTICENTER STUDY AZA-JMML-001

EHA Library, Charlotte M. Niemeyer, 267072

FAVORABLE OVERALL SURVIVAL OF IMETELSTAT-TREATED RELAPSED/REFRACTORY MYELOFIBROSIS PATIENTS COMPARED WITH CLOSELY MATCHED REAL WORLD DATA

EHA Library, Andrew Kuykendall, 267073

MAINTENANCE OF RESPONSE IN LONG-TERM TREATMENT WITH ROPEGINTERFERON ALFA-2B (BESREMI®) VS. HYDROXYUREA IN POLYCYTHEMIA VERA PATIENTS (PROUD/CONTINUATION-PV PHASE III TRIALS)

EHA Library, Heinz Gisslinger, 267074

RISK FACTORS AND OUTCOME OF ACUTE MYELOID LEUKEMIA SECONDARY TO POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT

EHA Library, Barbara Mora, 267075

FEDRATINIB IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASM (MPN)-ASSOCIATED MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX): A REANALYSIS OF THE PHASE 2 JAKARTA-2 STUDY

EHA Library, Claire Harrison, 267076

LONG-TERM FOLLOW UP OF JAK INHIBITOR (JAKI) TREATED PATIENTS WITH MYELOFIBROSIS: IMPACT OF MOLECULAR ENHANCED INTEGRATED SCORING SYSTEMS AND TYPE OF JAKI THERAPY FAILURE ON SURVIVAL

EHA Library, Caroline MCNAMARA, 267077

FAMILIAL OCCURRENCE OF SYSTEMIC AND CUTANEOUS MASTOCYTOSIS IN AN ADULT MULTICENTER SERIES: A REPORT OF 22 CLUSTERED CASES

EHA Library, Ilaria Tanasi, 267078

SECOND PRIMARY MALIGNANCIES IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: REAL WORLD EVIDENCE FROM 215 CONSECUTIVELY TREATED PATIENTS IN LOMBARDY

EHA Library, Margherita MAFFIOLI, 267079

SURVIVAL OUTCOMES IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: A POPULATION-BASED COHORT STUDY IN SWEDEN AND NORWAY

EHA Library, Frida Schain, 267080

INTERFERON ALPHA HAS STRONG ANTI-TUMOR EFFECT IN PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Patrizia Mondello, 267081

SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS WITH MYELOFIBROSIS (MF) AND ANEMIA (HB <10 G/DL): RESULTS AT WEEK (WK) 24 OF THE REALISE TRIAL

EHA Library, Francisco Cervantes, 267082

CYTOREDUCTION FOR THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA: A SYSTEMATIC REVIEW

EHA Library, Sarah Sloan, 267083

EARLY RESULTS OF A PHASE II STUDY OF COMBINED RUXOLITINIB AND THALIDOMIDE IN PATIENTS WITH MYELOFIBROSIS

EHA Library, Raajit K Rampal, 267084

IMPACT OF CYTOREDUCTIVE DRUGS ON SECOND CANCER IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Tiziano Barbui, 267085

IL28B GENE POLYMORPHISMS INFLUENCE ON THE RESPONSIVENESS AND TOLERABILITY OF IFN-Α IN PATIENTS WITH MPN

EHA Library, Marina Stolyar, 267086

EFFICACY AND SAFETY OF ANAGRELIDE IN OLDER PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA

EHA Library, Veronika Buxhofer-Ausch, 267087

MYELOPROLIFERATIVE NEOPLASMS IN KOREAN CHILDREN AND YOUNG ADULTS

EHA Library, Hyoung Soo Choi, 267088

CURRENT PRACTICE IN THE MANAGEMENT OF ESSENTIAL THROMBOCYTEMIA AND POLYCYTHEMIA VERA: A SURVEY FROM THE FRENCH INTERGROUP OF MYELOPROLIFERATIVE NEOPLASMS (FIM) AMONG 120 HEMATOLOGISTS AND INTERNISTS

EHA Library, Guillemette FOUQUET, 267089

ULTRASONOGRAPHY VS RM FOR SPLEEN VOLUME EVALUATION IN MYELOPROLIFERATIVE NEOPLASMS: WHAT YOU NEED TO KNOW.

EHA Library, Novella Pugliese, 267090

NON-HODGKIN LYMPHOMA IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Kentaro Yoshinaga, 267091

COATED PLATELET FUNCTION IS RELATED TO BLEEDING PHENOTYPE IN PATIENTS WITH INHERITED THROMBOCYTOPENIA

EHA Library, Nanna Brøns, 267092

APPLICATION OF WHOLE EXOME SEQUENCING FOR PATIENTS WITH INHERITED PLATELET DISORDERS

EHA Library, Marian Stevens-Kroef, 267093

PLATELET DISFUNCTION IN NOONAN AND 22Q11.2 DELETION SYNDROMES IN CHILDHOOD

EHA Library, Albert CATALA, 267094

EVALUATION OF COMBINED MEASUREMENT OF IMMATURE PLATELET FRACTION AND SCHISTOCYTES IN PREGNANCY-ASSOCIATED THROMBOTIC THROMBOCYTOPENIC PURPURA AND SEVERE PREECLAMPSIA/ HELLP SYNDROME

EHA Library, Rasha El-Gamal, 267095

INTERLEUKIN-37 REDUCES INFLAMMATION AND IMPAIRS PHAGOCYTOSIS OF PLATELETS IN IMMUNE THROMBOCYTOPENIA

EHA Library, Yajing Zhao, 267097

PLATELET REACTIVITY AND RESPONSE TO ANTIPLATELET DRUGS IN THROMBOCYTOPENIA AND THROMBOCYTOSIS

EHA Library, Lidia USNARSKA-ZUBKIEWICZ, 267098

EFFECT OF THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RAS) ON ENDOTHELIAL CELLS AND NEUTROPHIL EXTRACELLULAR TRAP (NET) FORMATION IN IMMUNE THROMBOCYTOPENIA (ITP)

EHA Library, Lamya Garabet, 267099

IMPACT OF NEXT GENERATION SEQUENCING ON DIAGNOSIS OF INHERITED THROMBOCYTOPENIAS

EHA Library, Daria Fedorova, 267100

NOVEL ADAMTS13 MUTATIONS IN A PATIENT OF INHERITED THROMBOTIC THROMBOCYTOPENIC PURPURA

EHA Library, Li Zhou, 267101

TRAMETINIB RESTORES IMMUNE TOLERANCE IN ITP PATIENTS BY MODULATING IRF4-MEDIATED TH1 AND TREG CELLS

EHA Library, Haoyi Wang, 267102

INTERLEUKIN-33 IN PEDIATRIC PATIENTS WITH IMMUNE THROMBOCYTOPENIA: RELATION TO PROGNOSIS AND TREATMENT OUTCOME

EHA Library, AZZA ABDELGAWAD TANTAWY ZAGHLOUL, 267103

EFFECT OF PLASMA EXCHANGE ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF CAPLACIZUMAB

EHA Library, Rui Sousa, 267104

ATYPICAL HAEMOLYTIC URAEMIC SYNDROME IN THE ECULIZUMAB ERA: PRESENTATION, RESPONSE TO TREATMENT AND EVALUATION OF AN ECULIZUMAB WITHDRAWAL STRATEGY

EHA Library, Lucy Neave, 267105

TH1 CYTOKINE IFN-GAMMA+874T/A AND TNF-ALPHA-857C/T POLYMORPHISMS AFFECT THROMBOCYTOPENIA IN CHRONIC IMMUNE THROMBOCYTOPENIA (CITP)

EHA Library, Kana Souma, 267106

BERBERINE MAY CORRECT GUT MICROBIOTA-INDUCED CORTICOSTEROID RESISTANCE AND MESENCHYMAL STEM CELL DYSFUNCTION IN IMMUNE THROMBOCYTOPENIA BY REGULATING GUT MICROBIOTA STRUCTURE

EHA Library, Yanan Wang, 267107

PLATELET KINETICS IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA TREATED WITH THROMBOPOIETIN RECEPTOR AGONISTS

EHA Library, Zlatko Pravdic, 267108

ASSESSING TREATMENT RESPONSE IN CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA WITH AN INNOVATIVE SHEAR FLOW-BASED ASSAY

EHA Library, Chiara Vendramin, 267109

NEXT-GENERATION SEQUENCING REVEALS DISTINCT EXPANDED T-CELL RECEPTOR (TCR) Β-CHAIN CLONOTYPES IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP)

EHA Library, Amna Malik, 267110

FUNCTIONAL ASSAYS USING WASHED PLATELETS FOR HEPARIN-INDUCED THROMBOCYTOPENIA DIAGNOSIS: A RETROSPECTIVE STUDY COMPARING HEPARIN- INDUCED PLATELET ACTIVATION TEST VERSUS 14C-SEROTONIN RELEASE ASSAY

EHA Library, Vasiliki Gkalea, 267112

ANKRD26-RELATED THROMBOCYTOPENIA: STUDY OF 3 FAMILIES

EHA Library, Daniela Pereira Coelho, 267113

NEUTROPHIL EXTRACELLULAR TRAPS (NETS), BLOOD CELL COUNTS AND THROMBOTIC RISK IN ITP PATIENTS

EHA Library, María Lozano, 267114

INCREASED RHOA ACTIVITY DUE TO A DISRUPTED FILAMIN A/ALPHAIIBΒETA3 INTERACTION INDUCES MACROTHROMBOCYTOPENIA

EHA Library, Alessandro Donada, 267115

THE EMOTIONAL IMPACT OF WATCH AND WAIT FOR CLL

EHA Library, Zack Pemberton-Whiteley, 267116

HEALTHCARE RESOURCE UTILIZATION (HCRU) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED (ND) ACUTE MYELOID LEUKEMIA (AML) TREATED IN THE CONNECT® MDS/AML DISEASE REGISTRY

EHA Library, Sudipto Mukherjee, 267117

QUALITY OF LIFE IN PATIENTS UNDERGOING CHIMERIC ANTIGEN RECEPTOR (CAR) - T CELL THERAPY VS. AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANT FOR HEMATOLOGIC MALIGNANCIES

EHA Library, Surbhi Sidana, 267118

VALIDATION OF HAND GRIP STRENGTH AS A SCREENING TOOL FOR FRAILTY IN OLDER PATIENTS ON TREATMENT FOR HEMATOLOGIC MALIGNANCIES: THE FRAILTY TASK FORCE STUDY

EHA Library, Tommasina GUGLIELMELLI, 267119

ESTIMATING LIFE-YEAR LOSS OF LOWER-RISK MYELODYSPLASTIC SYNDROMES IN EUROPE

EHA Library, Zhiyi Li, 267120

ASSESSMENT OF HM-PRO ITALIAN VERSION IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES IN CLINICAL PRACTICE

EHA Library, Esther N. Oliva, 267121

CLINICAL AND ECONOMIC BURDEN OF MYELOFIBROSIS IN A LARGE US MANAGED CARE POPULATION

EHA Library, Kejal Parikh, 267122

APREPITANT AS ADJUNCT FOR THE MANAGEMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN PATIENTS WITH HEMATOLOGIC MALIGNANCY UNDERGOING HIGHLY EMETOGENIC CHEMOTHERAPY: A META-ANALYSIS

EHA Library, Feroni Pella Panjaitan, 267123

INCREASED VOC FREQUENCY ASSOCIATED WITH REDUCED HRQOL AMONG PATIENTS WITH SCD

EHA Library, Miranda Bailey, 267124

QUALITY OF LIFE AND PERCEPTION OF HEALTH CARE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES IN THE UK

EHA Library, Esther N. Oliva, 267125

QUALITY OF LIFE IN PATIENTS WITH RRMM DURING IXA-THAL-DEX INDUCTION AND IXAZOMIB MAINTENANCE THERAPY IN COMPARISON TO THE GENERAL POPULATION

EHA Library, Heinz Ludwig, 267126

FLUPENTIXOL MELITRACEN COMBINED WITH ONDANSETRON IN PREVENTION OF NAUSEA AND VOMITING INDUCED BY CONDITIONING IN PATIENT TO UNDERGO HSCT

EHA Library, Ying Lu, 267127

THE FINANCIAL IMPACT OF ACUTE LEUKAEMIA

EHA Library, Charlotte Martin, 267128

THE DIAGNOSTIC YIELD OF BONE MARROW BIOPSY IN PATIENTS WITH LIVER FAILURE

EHA Library, Thinzar Ko Ko, 267129

ESTIMATING LIFE-YEAR LOSS OF PRIMARY MYELOFIBROSIS IN EUROPE

EHA Library, Zhiyi Li, 267130

PARTICIPATION IN A SPECIALISED EXERCISE INTERVENTION IMPROVED PHYSICAL FUNCTION AND HEALTH-RELATED QUALITY OF LIFE IN PEOPLE WITH HAEMATOLOGICAL CANCERS

EHA Library, Jennifer Nicol, 267131

PREMEDICATION WITH MONTELUKAST AND RUPATADINE DECREASES INFUSION TIME, RATE AND SEVERITY OF REACTIONS AND OVERALL COST OF RITUXIMAB ADMINISTRATION

EHA Library, Rouslan Kotchetkov, 267132

COST-EFFECTIVENESS OF RISK-STRATIFIED TREATMENT IN TRANSPLANT-ELIGIBLE PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Annemieke van Dongen - Leunis, 267133

MILD COGNITIVE IMPAIRMENT, HYPOALBUMINEMIA, HIGH CRP AND GASTRO-INTESTINAL ULCER: 4 MARKERS OF FRAILTY WHICH IDENTIFY OLDER PATIENTS WITH MALIGNANT HEMOPATHIES WHO DON’T BENEFIT FROM CHEMOTHERAPY

EHA Library, Vincent Thibaud, 267134

GENOME EDITING OF HBG1/2 PROMOTER LEADS TO ROBUST HBF INDUCTION IN VIVO, WHILE EDITING OF BCL11A ERYTHROID ENHANCER RESULTS IN ERYTHROID DEFECTS

EHA Library, Kaihsin Chang, 267135

DECREASED ACTIVITY AND STABILITY OF PYRUVATE KINASE IN SICKLE CELL DISEASE AND THALASSEMIA: A POTENTIAL TARGET FOR THERAPY

EHA Library, Minke Rab, 267136

INCENTIVE SPIROMETRY TO PREVENT ACUTE CHEST SYNDROME IN ADULTS WITH SICKLE CELL DISEASE; A MULTICENTER RANDOMIZED CLINICAL TRIAL

EHA Library, Charlotte van Tuijn, 267137

THE SOLUBLE GUANYLATE CYCLASE STIMULATOR OLINCIGUAT ATTENUATES LEUKOCYTE/ENDOTHELIAL CELL INTERACTIONS IN BERKELEY SCD MICE

EHA Library, Huihui Li, 267138

CENTRAL PHYSIOLOGIC MECHANISMS WHICH AUGMENT OXYGEN RELEASE (BOHR EFFECT AND 2,3-DPG BINDING) ARE PRESERVED IN THE PRESENCE OF VOXELOTOR AT THE THERAPEUTIC TARGET OF 30% HB MODIFICATION

EHA Library, Mira Pochron, 267139

THE OXYGENSCAN: A COMPREHENSIBLE FUNCTIONAL RED BLOOD CELL TEST TO MONITOR TREATMENT EFFICACY IN PATIENTS WITH SICKLE CELL DISEASE

EHA Library, Minke Rab, 267140

WHEN IS A CT NEEDED TO DIAGNOSE ACUTE PULMONARY EMBOLISM IN INDIVIDUALS WITH SICKLE CELL DISEASE

EHA Library, Nadirah El-Ahmin, 267141

ANTISICKLING EFFECTS OF 1,2,3-TRIAZOLE DERIVATIVES AS POTENTIAL NEW DRUGS FOR SICKLE CELL DISEASE

EHA Library, Clemilson Berto-Junior, 267142